Showing results (51-60 of 87) with videos related to

Sort By:
Pageof 9
Blood|December 6, 2021
Impact of high-risk cytogenetics on outcomes for children and young adults receiving CD19-directed CAR T-cell therapyAllison Barz Leahy, Kaitlin J Devine, Yimei Li, et al.
Blood Advances|February 17, 2026
CD19 CAR T-cell outcomes in relapsed/refractory extramedullary B-ALL: a multi-site, retrospective cohort reviewAlexander W Rankin, Regina M Myers, Adam J Lamble, et al.
Haematologica|January 30, 2025
Integrated genomic analysis to reduce chromosomal analysis for the diagnosis of pediatric hematologic malignancies: addressing the shortage of cytogenetic technologistsDong Li, Sarah K Tasian, Gerald Wertheim, et al.
Leukemia|October 31, 2022
Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemiaValeria Ceolin, Erica Brivio, Harm van Tinteren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2022
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621Maureen M O'Brien, Lingyun Ji, Nirali N Shah, et al.
Pediatric Blood & Cancer|November 20, 2013
Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemiaAlix E Seif, Brian T Fisher, Yimei Li, et al.
Leukemia|March 8, 2019
Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Blood|June 21, 2024
Quadriparesis and paraparesis following chimeric antigen receptor T-cell therapy in children and adolescentsCaroline Diorio, Laura Hernandez-Miyares, Diego A Espinoza, et al.
Blood|June 22, 2018
Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphomaJakub Svoboda, Susan R Rheingold, Saar I Gill, et al.
Leukemia|September 30, 2018
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemiaDeepa Bhojwani, Richard Sposto, Nirali N Shah, et al.
Pageof 9